Brief: Provectus Announces Presentation Of Preliminary Results From Phase 1 Trial Of PV-10
12/12/2019 13:40
Dec 12 (Reuters) - Provectus Biopharmaceuticals Inc
PVCT.PK :
* PROVECTUS ANNOUNCES PRESENTATION OF PRELIMINARY RESULTS
FROM
PHASE 1 TRIAL OF PV-10® (ROSE BENGAL DISODIUM) FOR TREATMENT OF
METASTATIC UVEAL MELANOMA AT ESMO I-O CONGRESS 2019
Source text for Eikon: ID:nGNX20T71D
Further company coverage: PVCT.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Provectus Biopharmaceuticals
See all newsBrief: Provectus Biopharmaceuticals Reports Oral Pv-10 Anti-Tumor Activity In Preclinical Bladder Cancer Study
Brief: Provectus Biopharmaceuticals Initiates Preclinical Study Of Oral Pv-10
RCS - VisiRose - VisiRose Introduces Therapy for Eye Infections
RCS - FINOS - FINOS Welcomes Seven Financial Leaders
Brief: Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting